Tissue Microarray Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Global Tissue Microarray Market is Segmented by Procedure (Immunohistochemistry, Fluorescence in situ hybridization (FISH), In Situ Hybridization, and Other Product Types), Technology (Polymerase Chain Reaction, Next-Generation Sequencing, DNA Microarray, and Other Technology Types), End User (Pharmaceutical and Biotechnological Companies, and Research Organizations, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

tissue microarray market
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: >10 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The global tissue microarray market is expected to register a CAGR of more than 10% during the forecast period (2022-2027).

The COVID-19 pandemic is an unprecedented health concern and has significantly impacted the tissue microarray market. The COVID-19 pandemic has turned a spotlight on the molecular diagnostics industry across the world, with the rapid development of diagnostics, fast-tracked regulatory clearances, and ramped-up distribution in various regions to help curb the spread of the virus. For instance, as per a January 2022 published article titled, "Systematic Investigation of SARS-CoV-2 Receptor Protein Distribution along Viral Entry Routes in Humans", tissue microarrays incorporating a total of 879 tissue cores from conjunctival (n = 84), sinonasal (n = 95), and lung (bronchiolar/alveolar; n = 96) specimens were investigated for protein expression by immunohistochemistry. The study confirms and extends previous findings and contributes to a better understanding of potential SARS-CoV-2 infection sites along the human respiratory tract. Such studies indicate significant demand for tissue microarray products amid the pandemic. Also, with the introduction of vaccines and the upliftment of lockdown restrictions, the market is expected to witness positive growth in the coming period.

The growth of the market can be attributed to the factors such as research and development in drug discovery, the rising burden of cancer, and increasing demand for accurate methods.

The rising prevalence of cancer is driving the demand for tissue microarray products. For instance, according to the World Health Organization (WHO), cancer accounted for approximately 10 million deaths in 2020. The International Agency for Research on Cancer (IARC) predicts that, by 2030, the global burden is expected to increase to 21.7 million new cancer cases and 13 million cancer deaths due to the growth and aging of the population, apart from other factors, such as smoking, poor diet, physical inactivity, and fewer childbirths. The tissue diagnostics capture the disease insights and the parameters that factor into the patient outcomes. Additionally, according to GLOBOCAN 2020, the estimated number of new cases of breast cancer cases in 2020 was 2.26 million, and the number is estimated to reach 3.19 million by the year 2040. Thus, the demand for tissue microarrays is increasing owing to the growing burden of cancer.

Additionally, strategic initiatives taken by market players are also propelling the growth of the market. For instance, in March 2021, Oxford BioDynamics Plc and Agilent Technologies signed a supply and resale agreement for the manufacture and sale of the new EpiSwitch Explorer Array Kit.

However, the availability of alternative technologies and the high cost associated with microarray techniques are the factors hindering market growth.

Scope of the Report

As per the scope of the report, tissue microarrays are referred to as paraffin blocks produced by extracting cylindrical tissue cores from different paraffin donor blocks and re-embedding these into a single recipient (microarray) block at defined array coordinates. The market is segmented by procedure (immunohistochemistry, fluorescence in situ hybridization (FISH), in situ hybridization, and other product types), technology (polymerase chain reaction, next-generation sequencing, DNA microarray, and other technology types), end user (pharmaceutical and biotechnological companies, and research organizations, and other end users), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Procedure
Immunohistochemistry
Fluorescence in situ hybridization (FISH)
In Situ Hybridization
Other Procedure Types
By Technology
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing
DNA Microarray
Other Technology Types
By End User
Pharmaceutical and Biotechnological Companies
Research Organizations
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Immunohistochemistry Segment is Expected to Hold a Major Market Share in the Tissue Microarray Market

By procedure, the immunohistochemistry segment is expected to hold a major share in the market. Immunohistochemistry is one of the most common applications of immunostaining. It involves the process of selectively identifying antigens in cells of a tissue section by exploiting the principle of antibodies binding specifically to antigens in biological tissues. The major factors fueling the market growth are the increasing application of immunohistochemistry in tissue diagnostics as well as the growing research and development. For instance, as per the study published in February 2022, titled 'Novel Rapid Immunohistochemistry Using an AlternatingCcurrent Electric Field Identifies Rac and Cdc42 Activation in Human Colon Cancer FFPE Tissues', the scientists developed a novel detection technique for activated Rac/Cdc42 in human cancer FFPE tissues using a recently developed rapid immunohistochemistry (R-IHC) device, in which the antigen-antibody reaction can be facilitated up to 1,200-fold by alternating current-based high-speed microaggitation.

Additionally, the launch of new products is also propelling the growth of the market. For instance, in March 2021, Roche launched the DISCOVERY Green HRP kit. It is the newest addition to the comprehensive collection of modular-based detection kits to identify and profile biomarkers and cell populations in tissue-based research. The DISCOVERY Green HRP (horseradish peroxidase) kit can be used in combination with other detection kits, expanding the multiplexing capability of both immunohistochemistry (IHC) and in situ hybridization (ISH) by providing a distinct color that contrasts with other chromogens. Such launches also boost the growth of the market segment.

Thus, due to the above-mentioned factors, the market is expected to witness significant growth over the forecast period.

Number of New Cancer Cases, All Ages, Global, 2020

North America is Expected to Hold a Significant Share in the Market and Expected to do Same Over the Forecast Period

Within North America, the United States has held a major share of the market. The major factors contributing to the market growth are the presence of many market players engaged in manufacturing and expanding the portfolio of instruments and reagents for molecular diagnostic testing. The region also witnesses the presence of well-established healthcare diagnostic facilities.

For instance, as per the 2020 Statistics by the National Cancer Institute (NCI), about 1,806,590 cases of cancer were diagnosed in the United States in 2020, and the number of cancer survivors is projected to reach 2.2 million by 2030. Moreover, as per the NCI, in 2021, the most prevalent cancer type is breast cancer, with 284,200 cases. These factors are leading to an increased demand for DNA repair drugs in the region.

In addition, as per a 2020 report by the American Cancer Society, several professional associations, including the National Comprehensive Cancer Network (NCCN), the American Association of Clinical Oncology (ASCO), and the College of American Pathologists (CAP), have developed biomarker testing and treatment guidelines.

Several market players are also engaged in the implementation of strategic initiatives, thereby contributing to market growth. For instance, in July 2021, BioIVT, one of the leading providers of research models and services for drug and diagnostic development, acquired Tissue Solutions Ltd. Tissue Solutions provides medical researchers with high-quality human tissue and other biological materials for use in drug discovery, target identification and validation, assay development and validation, and biomarker and companion diagnostic development.

Thus, due to the above-mentioned developments, the market is expected to witness significant growth over the forecast period.

 tissue microarray market size

Competitive Landscape

The tissue microarray market is competitive with the presence of several global and international market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are Novus Biologicals, OriGene Technologies, Inc, ProteoGenex, PREMIER Biosoft, and BioIVT, among other players.

Recent Developments

  • In March 2022, Boston Cell Standards, a company dedicated to ensuring that cancer patients receive accurate diagnosis and treatment, launched the Consortium for Analytic Standardization in Immunohistochemistry (CASI). The new organization is led by an international panel of pathologists and scientists dedicated to improving patient immunohistochemistry (IHC) test accuracy and reproducibility.
  • In January 2022, Histobiolab, a division of Creative Bioarray, reported that it had developed a professional tissue microarray to meet precise research needs.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Research and Development in Drug Discovery

      2. 4.2.2 Rising Burden of Cancer

      3. 4.2.3 Increasing Demand For Accurate Diagnostic Methods

    3. 4.3 Market Restraints

      1. 4.3.1 Availability of Alternative Techniques

      2. 4.3.2 High Cost Associated With Microarray Techniques

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value- USD million)

    1. 5.1 By Procedure

      1. 5.1.1 Immunohistochemistry

      2. 5.1.2 Fluorescence in situ hybridization (FISH)

      3. 5.1.3 In Situ Hybridization

      4. 5.1.4 Other Procedure Types

    2. 5.2 By Technology

      1. 5.2.1 Polymerase Chain Reaction (PCR)

      2. 5.2.2 Next-Generation Sequencing

      3. 5.2.3 DNA Microarray

      4. 5.2.4 Other Technology Types

    3. 5.3 By End User

      1. 5.3.1 Pharmaceutical and Biotechnological Companies

      2. 5.3.2 Research Organizations

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Novus Biologicals

      2. 6.1.2 ProteoGenex

      3. 6.1.3 PREMIER Biosoft

      4. 6.1.4 OriGene

      5. 6.1.5 Biocompare

      6. 6.1.6 BioIVT

      7. 6.1.7 US Biolab

      8. 6.1.8 Arrayit Corporation

      9. 6.1.9 Protein Biotechnologies

      10. 6.1.10 Applied Microarrays

      11. 6.1.11 BioCat GmbH

      12. 6.1.12 Bio SB

      13. 6.1.13 Creative Bioarray

      14. 6.1.14 Abcam

      15. 6.1.15 Auria Biobank

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Tissue Microarray Market market is studied from 2019 - 2027.

The Global Tissue Microarray Market is growing at a CAGR of >10% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Novus Biologicals, OriGene Technologies, Inc, ProteoGenex, PREMIER Biosoft, BioIVT are the major companies operating in Global Tissue Microarray Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!